Early palliative care in newly diagnosed cancer in Ethiopia: feasibility randomised controlled trial and cost analysis.

COVID-19 Cancer

Journal

BMJ supportive & palliative care
ISSN: 2045-4368
Titre abrégé: BMJ Support Palliat Care
Pays: England
ID NLM: 101565123

Informations de publication

Date de publication:
22 Nov 2022
Historique:
received: 18 10 2022
accepted: 02 11 2022
entrez: 22 11 2022
pubmed: 23 11 2022
medline: 23 11 2022
Statut: aheadofprint

Résumé

Globally, cancer deaths are rising. In low-and-middle-income countries, there is a gap in access to palliative care (PC). We designed a feasibility trial to study the initiation of early PC in patients with cancer in Addis Ababa, Ethiopia. A randomised controlled trial (RCT) of standard cancer care versus standard cancer care plus in-home PC was conducted. Follow-up was at 8 and 12 weeks. Primary outcomes were: (1) feasibility, (2) patient-reported PC outcomes (African Palliative Care Association Palliative Outcome Scale (APCA POS)), and (3) costs. Of 95 adults randomised (mean age 49.5 years; 66% female), 27 completed 3 study visits. Of these, 89% had stage III or IV disease. Recruitment was feasible, but attrition was high. APCA POS use was feasible, with significant within-arm improvements: 24% versus 18% reduction (p<0.0002, p<0.0025) in PC versus standard care, respectively. Standard care subjects reported higher out-of-pocket payments (5810 Ethiopian birr) (ETB) and lost wages of informal caregivers (74 900 ETB), multiple times an average Ethiopian salary (3696 ETB). It is feasible to conduct an RCT of early PC for patients with cancer in Ethiopia. Retention was the biggest challenge. This study revealed opportunities to improve care, and important feasibility results to inform future, larger scale PC research in Ethiopia and beyond.

Identifiants

pubmed: 36414402
pii: spcare-2022-003996
doi: 10.1136/spcare-2022-003996
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Eleanor Anderson Reid (EA)

Department of Emergency Medicine, Yale School of Medicine, New Haven, Connecticut, USA eleanor.reid@yale.edu.
Usher Institute, Center for Population Health Sciences, University of Edinburgh Division of Medical and Radiological Sciences, Edinburgh, UK.

Ephrem Abathun (E)

Hospice Ethiopia, Addis Ababa, Ethiopia.

Jilcha Diribi (J)

Department of Oncology, Addis Ababa College of Health Sciences School of Medicine, Addis Ababa, Ethiopia.

Yoseph Mamo (Y)

Hospice Ethiopia, Addis Ababa, Ethiopia.

Tigeneh Wondemagegnhu (T)

Department of Oncology, Addis Ababa College of Health Sciences School of Medicine, Addis Ababa, Ethiopia.

Peter Hall (P)

Department of Oncology, University of Edinburgh Western General Hospital, Edinburgh, UK.

Marie Fallon (M)

Palliative Medicine, University of Edinburgh Western General Hospital, Edinburgh, UK.

Liz Grant (L)

Programme Director Global Health: Non Communicable Diseases, University of Edinburgh Global Health Academy, Edinburgh, UK.

Classifications MeSH